People with primary ocular adnexal MALT lymphomas (POAML) have a high risk of relapse and progression to aggressive lymphoma, according to a retrospective analysis involving 182 individuals.

Participants all had POAML (mostly stage I) and were treated at a single institution. Investigators analyzed long-term outcomes, response to treatment, incidence and localization of relapse, and transformation. Among the results:

• 84% completely responded to first-line therapy.
• In patients with stage I disease who were treated with radiation therapy, doses ≥30.6Gy were linked with better complete response and progression free survival at 5 and 10 years.
• Median overall and progression-free survival were 250 and 134 months, respectively.
• Patients >60 years of age were more than twice as likely to have shorter progression-free survival.
• Those who received radiotherapy were more than 4 times as likely to have shorter progression-free survival.